Evidence map›Paper›PMID 38251828›Full record

ArticleClinical and translational medicine2024

Urinary DNA methylation-based risk stratification model to triage patients for repeat transurethral resection of bladder tumours.

Wei Ouyang, Ran Xu, Hanyu Yao, Shusuan Jiang, Qiang Lu, Cai Lv, Pei Li, Genming Xu, Jianye Liu, Long Wang

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Wei OuyangDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha, China.
Ran XuDepartment of Urology, The Second Xiangya Hospital, Central South University, Changsha, China.
Hanyu YaoDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha, China.
Shusuan JiangDepartment of Urology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medical, Central South University, Changsha, China.
Qiang LuDepartment of Urology, Hunan Provincial People's Hospital, First Affiliated Hospital of Hunan Normal University, Changsha, China.
Cai LvDepartment of Urology, Affiliated Haikou Hospital of Xiangya Medical College, Central South University, Haikou, China.
Pei LiYearth Biotechnology Co. Ltd., Changsha, China.
Genming XuYearth Biotechnology Co. Ltd., Changsha, China.
Jianye LiuDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha, China.
Long WangDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha, China.ORCID 0000-0003-4583-2428

Funding

Bethune Special Research Fund Project of Urological Oncology mnzl202006Hunan High-Tech Industry Science and Technology Innovation Leading Plan 2020SK2012the National Key R&D Program of China 2022YFE0200800the National Key R&D Program of China 2023YFC2507000
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

DNA MethylationUrinary Bladder NeoplasmsHumansRisk AssessmentTransurethral Resection of BladderTriage

Identifiers

PMID38251828
PMCPMC10802133

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.